Pascal Biosciences Discovers Cannabinoids Activate the Major Histocompatibility Complex to Aid Cancer Treatment

VANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, Sept 23, 2019 –Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”) today revealed the mechanism whereby cannabinoids may directly aid in cancer treatment.

Specific cannabinoids identified by Pascal scientists enhance the immunogenicity of tumor cells, rendering them more susceptible to recognition and elimination by the immune system. Besides combatting infection, one of the key roles of the immune system is to identify and eliminate cancer cells that can arise during the normal course of cell growth in healthy individuals. The Major Histocompatibility Complex (“MHC”) is the cellular machinery that flags tumor cells for the immune system. However, most metastatic tumor cells have lost their MHC expression, and thus escape immune system killing. Specific cannabinoids reactivate MHC expression and may restore immune cell destruction of tumors. This could aid cancer treatment, particularly by boosting the efficacy of checkpoint inhibitors, an exciting form of immunotherapy that is only effective in a fraction of patients.

Pascal first discovered that cannabinoids can stimulate the immune system to destroy tumor cells in February 2018. Since then, Pascal has tested over 400 natural and synthetic cannabinoids in Pascal’s proprietary assays. Pascal has further studied the immune activities that occur with cannabinoid treatment.

Pascal CEO Patrick Gray will present these exciting results at the CannMed 2019 Conference – Inspiring Science, Community & Hope – taking place September 23-24 at the Pasadena Convention Center in Pasadena, CA.

“We have made great progress since first announcing our results last year. We now have a much better understanding of the interplay between cannabinoids, the immune system, and cancer,” said Dr. Gray. “This work has enabled us to choose a specific cannabinoid with a good safety profile for human testing. We are nearing clinical development and we have the scientific understanding and patent protection to move our product forward.”

About Pascal Biosciences Inc.

Pascal is a biotechnology company focused on advancing innovative approaches for the treatment of cancer including cannabinoid-based therapeutics and targeted therapies. The Company’s leading portfolio comprises a small molecule therapeutic, PAS-403, that is advancing into clinical trials for the treatment of glioblastoma, and PAS-393, an immuno-stimulatory cannabinoid to be used in combination with checkpoint inhibitor therapy. In addition, Pascal is developing a B-cell targeted antibody for acute lymphoblastic leukemia. For more information, visit


Media Contact:
Julie Rathbun
Tel: 206-769-9219


Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.